

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

15

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 38/27, 38/28, 38/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/09060</b> <b>(43) International Publication Date:</b> 13 March 1997 (13.03.97)
<b>(21) International Application Number:</b> PCT/US96/14286 <b>(22) International Filing Date:</b> 6 September 1996 (06.09.96) <b>(30) Priority Data:</b> 60/003,473 8 September 1995 (08.09.95) US <b>(71) Applicant (for all designated States except US):</b> ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BRODERICK, Carol, L. [US/US]; Rural Route 2, Box 143 A, Monrovia, IN 46157 (US). DIMARCHI, Richard, D. [US/US]; 10890 Wilmington Drive, Carmel, IN 46033 (US). HEIMAN, Mark, L. [US/US]; 7523 Brookview Circle, Indianapolis, IN 46250 (US). STRAMM, Lawrence, E. [US/US]; 9143 Hadway Drive, Indianapolis, IN 46256 (US). <b>(74) Agents:</b> MACIAK, Ronald, S. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).		<b>(81) Designated States:</b> AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHOD OF TREATING INSULIN RESISTANCE  <b>(57) Abstract</b>  The present invention is in the field of human medicine, particularly in the treatment of Non-Insulin Dependent Diabetes Mellitus (NIDDM) and other insulin resistant states such as those associated with obesity and aging. The invention provides a method of treating insulin resistant mammals, which comprises administering to a mammal in need thereof a growth hormone releasing agent.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

-1-

## METHOD OF TREATING INSULIN RESISTANCE

The present invention is in the field of human medicine, particularly in the treatment of Non-insulin Dependent  
5 Diabetes (NIDD) and other insulin resistant states such as those associated with obesity and aging.

In 1930 Houssay and Biasotti demonstrated in dog that removal of the anterior pituitary ameliorates the  
diabetic symptoms (hyperglycemia, glycosuria, ketonuria)  
10 resulting from previous pancreatectomy. Houssay, B. A. et al., Compt. Rend. Soc. Biol. 104:407 (1930). Houssay continued these studies by injecting pituitary extract into the hypophysectomized, pancreatectomized dog and reported that the improvement in the diabetic condition was abolished.  
15 Houssay, B. A. et al., N. Engl. J. Med. 214:961 (1936). Houssay speculated that the primary pituitary factor for this anti-insulin-like action was growth hormone (GH). More recently, these studies have been confirmed in normal dogs. Indeed, when GH was administered for 32 to 44 days the  
20 treatment caused a profound insulin antagonism that initially resulted in increased insulin secretion accompanied by elevated fasting plasma glucose (increased insulin resistance) with eventual exhaustion of the pancreatic  $\beta$ -cell and development of permanent diabetes. Pierluissi, J. et  
25 al., Diabetologia 18: 223 (1980).

Diabetogenic actions of GH have also been reported in human. Several studies have examined insulin sensitivity in acromegalic patients. Glucose utilization and suppression of hepatic glucose production was impaired during euglycemic  
30 clamps. Hansen, I. et al., Am. J. Physiol. 250:E269 (1986). Forearm muscle glucose uptake after insulin infusion was also decreased in acromegalics. Galbraith, H. et al., Diabetes 9:459 (1960). Impaired glucose tolerance and hyperinsulinemia were reversed by either pituitary surgery,  
35 Levin, S.R. et al., Am. J. Med. 57:526 (1974), or

-2-

bromocriptine therapy, Feek, C.M. et al., J. Clin. Endocrinol. 22:532 (1981). As in acromegalic patients, GH administration to normal volunteers resulted in impaired suppression of hepatic glucose production, decrease glucose utilization, and insulin resistance. Rizza, R.A. et al., Diabetes 31:663 (1982); Bratusch-Marrain, P.R. et al., J. Clin. Endocrinol. Metab. 55:973 (1982) and Fineberg, S.E. et al., Diabetes 23:499 (1974). Because human GH is now readily available, there is increased potential to use it to treat conditions other than GH-deficient children. Recently, Sharp, Beshyah and Johnston, Sharp, P.S. et al., Bailliere Clin. Endo. 6:819 (1992), have warned that when considering such therapies one also need consider iatrogenic secondary diabetes.

These anti-insulin actions of GH aggravate the metabolic problems of patients with insulin dependent diabetes mellitus (IDDM) or Type I diabetes since GH is elevated in those diabetics. Schaper, N.C. ACTA Endocrinol. (Copenh) 122:7 (1990). Elevated GH in IDDM is thought to play an important role in diabetic complications, especially proliferative retinopathy. Holly, J. M. P. et al., J. Endocr. 118:353 (1988). Thus, GH suppression is a likely strategy to treat IDDM. Shumak, S.T. et al., Clin. Invest. Med. 13:287 (1990); Alzaid, A.A. et al., Diabetes Care 17:531 (1994).

In contrast to IDDM patients with little or no insulin secretion, non-insulin dependent diabetics (NIDDM) that are obese as well as non-diabetic obese individuals have elevated circulating insulin associated with depressed GH values. Meistas, M.T. et al., Metabolism 31:1224, (1982). Because insulin promotes storage of fuel as adipose and glycogen and that GH counters this action, low GH levels observed in obesity contribute further to development of adiposity. Thus, it would be desirable to treat obese individuals with GH or an agent that physiologically elevates

-3-

GH. However, as described above, GH therapy has been demonstrated to counter insulin actions and therefore is contraindicated for individuals with diabetes or for those who are at risk for diabetes. Never-the-less, there have been several trials to examine GH therapy in obese individuals. Gertner, J.M. Horm. Res. 40:10 (1993). Data is far from convincing that such treatment promotes significant loss of fat tissue and there is no data that examined either insulin secretion or insulin sensitivity.

10 An alternative therapy to GH is to stimulate endogenous GH release by GH-releasing hormone (GHRH). Indeed, some consider this a more physiological approach. Both GHRH and a combination of GHRH with GH-Releasing peptides (GHRPs) have been tested in obese individuals. 15 These studies demonstrated that the GH response to secretagogue is blunted in obesity. Kopelman, P.G. et al., J. Clin. Endocrinol. 23:87, (1985); Csizmadi, I. et al., Metab. 38:1016, (1989); DeMarinis, L. et al., J. Clin. Endocrinol. Metab. 74:1253, (1992); Cordido, F. et al., J. Clin. Endocrinol. Metab. 76:819 (1992); and Ghigo, E. et al., Horm. Metab. Res. 25:305 (1993). Since the intent of these studies was to test pituitary responsiveness to GH secretagogues in obesity and not to treat the pathophysiologic state, the pituitary challenge was acute and there were no attempts to measure insulin sensitivity or 25 pancreatic insulin reserve.

Chronic combined administration of GHRH and GH-releasing hexapeptide has been studied in obese Zucker rats. Bercu, B.B. et al., Endocrinology 131:2800 (1992). The data 30 indicate that the treated obese rats had similar body composition and plasma insulin values as vehicle treated obese counter parts. Additionally, the treated group appeared to tolerate an interperitoneal glucose injection better than untreated obese animals.

-4-

Prior to the present invention, GHRH had not been examined in animal models of NIDDM. Most unexpectedly, when GHRH or a functional analog thereof is administered to a diabetic mammal during the period of insulin resistance but  
5 prior to  $\beta$ -cell failure, insulin sensitivity as well as insulin secretion is enhanced. Islet cell failure is spared.

Accordingly, the present invention discloses a new, effective therapy for treating mammals afflicted with Non-insulin Dependent Diabetes (NIDDM) and other insulin  
10 resistant states such as those associated with obesity and aging. This therapy is contrary to conventional understanding of the diabetogenic properties of GH.

The present invention provides a method of treating an insulin resistant mammal, which comprises administering to  
15 a mammal in need thereof a growth hormone-releasing agent. More particularly, the present invention provides a method of treating mammals afflicted with non-insulin dependent diabetes mellitus. Preferably, the mammals are afflicted with non-insulin dependent diabetes mellitus. Insulin  
20 resistant mammals includes mammals suffering from non-insulin dependent diabetes mellitus (NIDDM) and other insulin resistant states such as those observed in aging and obesity. Most preferably, the present invention is practiced in those patients who are afflicted with insulin resistance, but have  
25 not experience  $\beta$ -cell failure.

A growth hormone releasing agent is a compound, that promotes the release and synthesis of growth hormone from the pituitary gland. Such agents include, for example, native growth hormone-releasing hormone (GHRH), analogs of  
30 GHRH, and agonists of the GHRH receptor. A growth hormone releasing agent may be a protein or a small organic compound. Growth hormone releasing agents include pharmaceutically acceptable salts thereof.

GHRH is known in the art as somatocrinin, Growth  
35 hormone Releasing Factor (GRF), and Growth Releasing Hormone

-5-

(GRH). The primary structure of human GHRH is a polypeptide of the Formula (I): Unless otherwise indicated, amino acids are in the L configuration.

5 Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu  
Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser  
Arg Gln Gln Gly Glu Ser Asn Gln Glu Arg Gly Ala Arg Ala  
Arg Leu-NH<sub>2</sub> (SEQ ID NO: 1)

10 One of ordinary skill in the art would appreciate  
that fragments of GHRH, preferably the N-terminal 29  
residues, result in fully active forms of the protein.  
Likewise, chemical modifications, preferably to the C-  
terminal, result in fully active forms of the protein. These  
15 modifications to the native GHRH are referred to herein as  
functional analogs. Functional analogs of GHRH include, for  
example, analogs described in U.S. Patent Nos. 4,517,181,  
4,518,586, 4,528,190, 4,529,595, 4,563,352, 4,585,756,  
4,595,676, 4,605,643, 4,620,976, 4,626,523, 4,628,043, and  
20 4,689,318. Other functional analogs include those of Formula  
(I) wherein Ala at position 2 is substituted with Ile, Val,  
Thr, or Gly.

A number of additional functional analogs have been  
prepared to form longer lasting and/or more potent GHRH  
25 analogs, for example, D-amino acid residues in various  
regions of the GRF molecules are described in Lance, V.A., et al. Biochem. Biophys. Res. Commun. 119 265 (1984); Coy, D.H.,  
et al. Peptides 8(suppl. 1), 49 (1986)). Peptide bond  
isosteres are incorporated in the N-terminal region, in  
30 Tourwe, D. Janssen. Chim. Acta 3,3 (1985); Hocart, S.J., et al. J. Med.Chem. 33, 1954-58 (1990). Other active functional  
analogs of GHRH include those described in Biochemical and  
Biophysical Research Communications, 123:2, 854-861 (1984);  
Biochemical and Biophysical Research Communications, 122:1,  
35 304-310 (1984); Biochemical and Biophysical Research

-6-

Communications, 139:2, 763-770 (1986); Journal of Medicinal Chemistry, 30:1, 219-222 (1987); Peptide Research, 1:1 36-41 (1988); J. Med. Chem., 33, 1954-1958 (1990); Horm. Metab. Res., 23, 15-21 (1991); European Journal of Pharmacology, 204, 179-185 (1991); Int. J. Peptide Protein Res., 37, 14-20 (1991); Peptide Research, 5:4, 190-193 (1992); J. Med. Chem., 35, 3928-3933 (1992); Biochimica et Biophysica, 1122, 147-153 (1992); Int. J. Peptide Protein Res., 39 364-374 (1992); J. Endocrinol. Invest., 16, 793-798 (1993), J. Med. Chem., 36, 888-897 (1993); Biopolymers (Peptide Science), 37, 67-88 (1995); and Proc. Natl. Acad. Sci., 92, 4872-4876 (1995).

Particularly preferred functional analogs of GHRH include those analogs described in European Patent Publication No. EP 511 003. Hereinafter Formula II:

15        X1-Ala-Asp-Ala-Ile-Phe-Thr-A8-A9-Tyr-Arg-Lys-Val-Leu-  
           A15-Gln-Leu-Ser-Ala-Arg-Lys-A22-Leu-Gln-A25-Ile-A27-Ser-  
           Arg-Y-Z-T                                (SEQ ID NO:2)


wherein:

20            A8 = Asn, Ala, Leu, Ser, or Thr;  
               A9 = Ser, Ala, Leu, Thr, or Asn;  
               A15 = Gly, Ala, Thr, or Leu;  
               A22 = Ala or Leu;  
               A25 = Asp or Glu;  
 25            A27 = Met, Leu, or Norleucine;  
               Y = absent, or an amino acid sequence from 1 to 15  
                   amino acids;  
               Z = absent, or an amino acid sequence of from 1 to  
                   32 amino acids;  
 30            T = a carboxyl terminal group represented by the  
                   formula -COOR<sub>a</sub>, -CR<sub>a</sub>O, -CONHNHR<sub>a</sub>, -CON(R<sub>a</sub>)(R<sub>b</sub>)  
                   or CH<sub>2</sub>OR<sub>a</sub> wherein R<sub>a</sub> and R<sub>b</sub> independently are  
                   lower alkyl, hydrogen;



-7-

X1 is an acyl group represented by the formula



wherein

5  $R_1$  = hydrogen, methyl, ethyl, hydroxyethyl, phenyl,  
or phenyl substituted by halo, lower alkyl,  
lower alkoxy, hydroxy, nitro, amino,  
acetamido, trifluoromethyl,  $-CH_2-OH$ , or  
10 sulfamido; or a 5 or 6 membered heterocycle  
containing one or more of N, O, or S;


$a$  = zero, 1, 2, or 3;

$b$  = zero or 1;

$c$  = zero or 1;

$d$  = zero to 12;

15  $R_2$  = H,  $CH_3$ ,  $CH_2OH$ , p-hydroxybenzyl, or



$e$  = zero to 5;

$A$  = absent, O or S;


$B$  = carbonyl, sulfonyl and sulfinyl;

20  $R_3$  = methyl, ethyl, hydroxyethyl, amino, hydroxyl,  
phenyl, or phenyl substituted with halo,  
alkyl, alkoxy, hydroxy, nitro, amino,  
acetamido, or sulfamido, or a 5 or 6 member  
heterocycle containing one or more of N, O, or  
25 S;

or a pharmaceutically acceptable salt thereof.

Preferred GHRH analogs are those wherein X1 is

-8-



wherein

R<sub>1</sub> = phenyl or phenyl substituted by halo, lower  
alkyl hydroxy, nitro, or amino;

5 a = 0, 1 or 2;

b = 1;

R<sub>2</sub> = H; and

B = carbonyl.

10 Examples of groups represented by X<sub>1</sub> of Formula II include p-chloro hippuroyl, p-methyl hippuroyl, p-nitro hippuroyl, hippuroyl, p-hydroxy hippuroyl, 3-benzoyl propionyl, n-phthaloyl glycyl, N-phenylmalonamidoyl, p-methyl-N-phenylmalonamidoyl, or p-fluorohippuroyl.

15 In the definition of Formula II, the term "lower alkyl" refers to C<sub>1</sub>-C<sub>4</sub> alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and t-butyl; "lower alkoxy" refers groups such as methoxy, ethoxy, n-propoxy, t-butoxy and the like; "halo" refers to groups such  
20 as fluorine, chlorine, bromine and iodine; "substituted phenyl" refers groups such as phenyl substituted by one or two of the same or different groups selected from halo, lower alkyl, lower alkoxy, hydroxy, nitro, amino, acetamido or sulfonamido, exemplified by such groups as 4-chlorophenyl 3-iodophenyl, 2-fluorophenyl, 4-methylphenyl, 3-chloro-4-methylphenyl, 3-bromophenyl, 4-ethylphenyl, 3-ethoxyphenyl, 2-methoxyphenyl, 4-isopropoxyphenyl, 4-hydroxyphenyl, 3,4-dihydroxyphenyl, 2,4-dihydroxyphenyl, 4-nitrophenyl, 3-aminophenyl, 3-chloro-4-hydroxyphenyl, 2-acetamidophenyl, 4-  
25 sulfonamidophenyl, 3,4-dimethoxyphenyl, 2-fluoro-4-aminophenyl, and the like; "a 5 or 6 membered heterocycle containing one or more of N, O, or S" refers to the 5

-9-

membered heterocycles such as for example, pyrrole, thiophene, furan, imidazole, oxazole oxadiazole, thiazole, 1,3,4,-thiodiazole, asoxazole, and the like; and to 6-membered heterocycles such as for example, pyridine, pyrimidine, pyran, dihydropyran, thiazine, thiapyran, triazine and like 6-membered heterocycles. Such 5- and 6-membered heterocycles may also bear a substituent group such as lower alkyl, lower alkoxy, hydroxy, amino, or halo.

The designation "A20", "A21", etc., in reference to amino acid residues of the compound of Formula II, corresponds to the number of the particular amino acid when numbered consecutively from the amino terminus of the protein as it occurs in nature and in the literature. Such uniform numbering of amino acid residues of well characterized proteins is well known by those of ordinary skill in the art. Designations such as "des-Tyr-GHRH" are widely understood in the art as meaning the natural GHRH molecule lacking the amino-terminal tyrosine residue. Renumbering the remaining amino acid residues of the protein is unnecessary and may result in confusion. In the above example, it is understood that the amino acid occupying the second position in the naturally occurring protein would be the amino terminal residue but retain its designation as Ala2 for example. Similarly, Leu(27) hGHRH is understood by one of ordinary skill in the art as being human GHRH with position 27 substituted with Leu. Designations according to the well accepted amino acid designations of the different GHRH species will be followed herein.

Preferred peptides of the invention comprise compounds of the Formula II wherein Y is the 30-44 amino acid sequence of mature GHRH. Thus, preferred compounds of the invention comprise a compound of the Formula II wherein Y is the 30-44 amino acid sequence of the naturally occurring 30-44 amino acid sequence of the particular species of GHRH in

-10-

question. An especially preferred Y peptide comprises the 30-43 amino acid sequence human GHRH.

Preferred peptides of the invention are represented when Z is absent or comprises the 45-76 amino acid sequence of the naturally occurring 45-76 amino acid sequence of the GHRH from the particular species under investigation. A most preferred form of the peptide moiety represented by Z comprises the naturally occurring 45-76 amino acid GHRH sequence of a particular species wherein the lysine residues thereof are replaced by arginine residues and the methionine residues are replaced by leucine residues. For example, an especially preferred GHRH analog exists when, Z comprises the amino acid sequence

15 Gly-Arg-Gln-Val-Asp-Ser-Leu-Trp-Ala-Asp-Gln-Arg-Gln-Leu-Ala-Leu-Glu-Ser-Ile-Leu-Ala-Thr-Leu-Leu-Gln-Glu-His-Arg-Asn-Ser-Gln-Gly. (SEQ ID NO:3)

A further preferred amino acid sequence of Z comprises the amino acid sequence:

25 Gly-Arg-Gln-Val-Asp-Gly-Val-Trp-Thr-Asp-Gln-Gln-Gln-Leu-Ala-Leu-Glu-Ser-Thr-Leu-Val-Ser-Leu-Leu-Gln-Glu-Arg-Arg-Asn-Ser-Gln-Gly. (SEQ ID NO:4)

Preferred compounds of the invention comprise compounds of the Formula II wherein the Y and/or Z peptides are of a sufficient length such that high level expression in E. Coli is achieved.

30 Preferred compounds of the invention further comprise GHRH analogs where none, one, or more than one of the amino acids having a free amino group is chemically modified. For purposes of the present invention, "chemically modified" is defined as the derivitization of an amino acid's free amino group with an alkyl or hydroxyalkyl group. The extent of modification is controlled by the length of

35

-11-

reaction or the amount of reagent. It is preferred that all amino acids having a free amino group are chemically modified. Especially preferred is a GHRH which only has one free amino group that can be chemically modified. Such a compound has no lysine or methionine residues. Lysine and/or methionine-containing compounds are converted to compounds with a free amino group only at the N-terminus by replacing lysines with arginines and methionines with leucines.

The analogs of Formula II are prepared by methods appreciated in the art and described in European Patent Publication No. EP 511 003, herein incorporated by reference.

Growth hormone is known to be diabetogenic. Therefore, one skilled in the art would expect that stimulation of the GHRH receptor would exasperate the diabetic state. Therefore, it is most unexpected that treating insulin resistant patients with GHRH receptor agonists effectively treats insulin resistance. This unexpected activity is demonstrated, *in vivo*, in a Zucker Diabetic Fatty male rat (ZDF male rat assay) and *in vivo*, in an aged rat study.

Treating, as used herein, describes the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of a compound of present invention to prevent the onset of the symptoms or complications, alleviating the symptoms or complications, or eliminating the disease, condition, or disorder. Treating an insulin resistant mammal includes increasing insulin sensitivity and/or insulin secretion to prevent islet cell failure.

The instant invention further provides pharmaceutical formulations and medicaments comprising compounds useful in the present invention. The proteins, preferably in the form of a pharmaceutically acceptable salt, can be formulated for parenteral administration for the therapeutic or prophylactic treatment of NIDDM. For example,

-12-

compounds of the Formula (II) can be admixed with conventional pharmaceutical carriers and excipients. These compositions comprise proteins containing from about 0.1 to 90% by weight of the active protein, preferably in a soluble form, and more generally from about 10 to 30%. Furthermore, the present proteins may be administered alone or in combination with other agents. For intravenous (iv) use, the protein is administered in a commonly used intravenous fluid and administered by infusion. Such fluids, for example, physiological saline or Ringer's solution can be used.

For intramuscular preparations, a sterile formulation, preferably a suitable soluble salt form of a protein of the Formula (I) or (II), for example the hydrochloride salt, can be dissolved and administered in a pharmaceutical diluent such as pyrogen-free water (distilled) or physiological saline. A suitable insoluble form of the compound may be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, e.g. an ester of a long chain fatty acid such as ethyl oleate. Pharmaceutically acceptable preservatives such as an alkylparaben, particularly methylparaben, propylparaben, or butylparaben or chlorobutanol are preferably added to the formulation to allow multi-dose use. The formulation is preferably prepared in the absence of salt to minimize the ionic strength of the formulation.

A pharmaceutically effective dosage is an amount necessary to stimulate the GHRH receptor. The dosages administered to an insulin resistant mammal will be determined by the physician in the light of the relevant circumstances including the choice of growth hormone releasing agent administered, the condition of the mammal, and the chosen route of administration. The dosage ranges presented herein as well as the Examples are not intended to limit the scope of the invention in any way.

-13-

EXAMPLE 1ZDF male rat assay

A growth hormone releasing agent is continuously administered subcutaneously by use of an "Alzet" mini osmotic pump, on Zucker diabetic male rats. The treatment was started at approximately 6 weeks of age and continued for approximately 6-8 weeks. The experiment was designed to allow the study of changes in the typical plasma glucose and insulin level profiles with the progression of the diabetic disease state.

## Methods:

Zucker Diabetic Fatty (ZDF/Gmi<sup>TM</sup>-fa/fa) male rats were obtained from Genetic Models Inc. (Indianapolis, IN). The rats were maintained on Purina Formula 5008 rat chow (Purina Mills, Inc., St. Louis, MO) and housed in a light controlled room of alternating 12 hour cycles of light and dark. Rats were singly housed and given free access to food and water. At 5 weeks of age, an oral glucose tolerance test (OGTT: 16 hr fast, oral glucose concentration at 2.5 grams/kg body weight; Butler dextrose solution 50%, lot # 3342, Ft. Collins, CO; time points at 0, 30, 60, and 120 minutes) was given to each rat and their plasma assayed for glucose and insulin levels. At 6 weeks of age Alzet minipumps, containing a 1.5 inch polyethylene tube extensions (Model 2001, lot # 040401, 1.0 µl/hr, 7 days; Alza Corporation, Palo Alto, CA) were implanted subcutaneously. Animals were anesthetized with isoflurane at approximately 2-3% in oxygen. Each rat was shaved and a Povidone Iodine scrub was used at the site of implantation. A small incision was made above and just posterior to the shoulder. A small pocket was made and the pump placed in so the delivery portal was away from the incision. The incision was then closed with wound clips and the rat observed and kept warm until awake. At the end of 7 days the pumps were removed from the rat and a new pump implanted subcutaneously as

-14-

previously described. Pumps contained vehicle (PBS) or a growth hormone releasing agent (8 rats/group).

The GH releasing agent was prepared at concentrations of 625 and 62.5 µg/mL and loaded into Alzet  
5 pumps using sterile techniques. Body weight and food consumption were monitored once a week. Rats were bled from the tail for plasma glucose, insulin, and growth hormone levels weekly. One week prior to sacrificing the rats, an I.P. injection of tetracycline was given to each rat and then  
10 again the day before sacrificing (20 mg/mL; 0.5 mL/animal) to determine bone growth.

Assays: Plasma glucose concentrations were determined by the glucose hexokinase method (IL Test GLucose, lot # I1040502; Instrumentation Laboratory Company, Lexington,  
15 MA) with a model 2000 Monarch (Instrumentation Laboratory Company, Lexington, MA). Insulin was determined with a Coat-a-Count kit (Diagnostic Products Corporation, Los Angeles, CA) using a rat insulin standard (Lilly Research Laboratories, Indianapolis, IN). Glucagon was assayed  
20 with a double antibody procedure using guinea pig anti-glucagon (Catalog no. 1032; Linco Research, St. Louis, MO.), goat anti-guinea pig (lot # T67-7GZ-237); Lilly Research Laboratories, Indianapolis, IN) and <sup>125</sup>I-glucagon (DuPont New England Nuclear, Wilmington, DE). Growth hormone was assayed  
25 using rat growth hormone standard (purchased from Parlow, Torrance CA; rGH-RP-2, lot AFP-3190B), anti rGH (purchased from Parlow, Torrance CA; rGH-s-r, lot AFP411S), <sup>125</sup>I-rGH (Corning-Hazelton, Vienna, Virginia) and protein A IGSL100 (Enzyme Center, Malden, MA).

30

#### EXAMPLE 2

##### Aged Rat Study

Animals: Male Fischer 344 rats 26 months of age were randomly assigned to three treatment groups (8 animals per  
35 group). Animals were housed in individual cages in a



-15-

temperature and humidity-controlled environment and exposed to 12 h light/12 h dark lighting schedule (lights on at 0600h). Animals were fed *ad libitum* on a daily basis.

Treatments: Animals received daily injection (sc., 0.5 ml at 0700h) of vehicle; active compound, 2 µg/kg body weight for six weeks. At the end of the treatment period and one day prior to testing, food was removed and animals were fasted for 16 hours. Glucose tolerance test was initiated at 0700 h in conscious and freely moving rats. Blood was collected by tail clipping method. A control blood sample (0.2 mL) was collected before ingesting glucose (2.5 g/kg body weight). Subsequent blood samples were collected at 30, 60, 90 and 120 min. after glucose ingestion. Blood was collected on ice and glucose concentrations were determined by bichromatic

analysis using the IL Monarch Chemistry Systems (Cat. # 35199, Instrumentation Laboratory, MA). Plasma was separated and samples were kept frozen (-20°C) until assay for insulin concentrations using double antibody radioimmunoassay.

Young Fischer 344 rats (2 months of age) were purchased (Harlan, IN). Animals were housed for 2 weeks under the same conditions as described earlier. Glucose tolerance test was conducted as described and glucose and insulin concentrations were evaluated.

Area under the response curve was calculated using the trapezoidal method and data were analyzed by ANOVA with Duncan's multiple range test.

A functional analog of GHRH, p-methyl hippuroyl Leu(27) (1-44)OH hGHRH, disclosed in European Patent Publication No. EP 511 003 and known to be an agent capable of stimulating growth hormone release and representative of the activity of GHRH or a functional analog thereof, was evaluated in the ZDF Male rat assay and the aged rat assay. The results are demonstrated in Tables 1 through 3.

-16-

Table 1:

Final Body Weight and Composition in ZDF Rats Infused with a Functional GHRH Analog from 6-Weeks of Age to 14-Weeks of Age

Weight (g)	Control	0.001 µg/min	0.01 µg/min
Total Body Mass	340.58	327.06	388.16*
Lean Mass	340.58	327.06	388.16*
Liver	22.12	22.21	24.79
Spleen	0.83	0.8	1.18
Epididymal Fat	0.26	0.25	0.33
Heart	1.52	1.44	1.69
Thymus	0.81	0.86	0.99

5

<sup>1</sup>Analog infusion was started at 6 weeks of age and was maintained until 14 weeks of age. Values are the mean of 8 individual animals. \* Denotes statistically significant (p<0.05).

10

Table 2

Mean Plasma Glucose and Plasma Insulin Levels During Continuous Infusion of Functional Analog<sup>1</sup>

AGE (weeks)	Plasma Glucose (mg/dl)		
	Control	0.001 µg/min	0.01 µg/min
6	140.51	139.99	139.86
7	157.31	155.34	148.68
8	204.24	183.41	165.01
9	299.18	331.91	215.49
10	359.68	389.18	235.91
11	410.40	392.65	232.89*
12	454.40	496.75	317.11*
13	458.41	446.03	248.28*
14	484.47	461.40	229.36*

15

-17-

Plasma Insulin (ng/ml)

6	10.90	9.81	11.21
7	22.76	23.91	24.76
8	27.42	27.33	26.81
9	24.37	21.11	24.23
10	23.20	20.18	27.85
11	20.60	20.98	30.05*
12	19.84	21.48	36.45*
13	18.41	16.29	29.92*

<sup>1</sup>GHRH analog infusion was started at 6 weeks of age and was maintained until 14 weeks of age. Values are the mean of 8 individual animals. \* Denotes statistically significant

5 (p<0.05).

Table 3

Oral Glucose Tolerance in Aged Rats is Improved by Daily Treatment with GHRH Analog

10

Plasma Glucose (mg/dL)

Time (min)	Young	Aged Control	Aged GHRH
0	104.4	110.7	104.2
30	116.4	160.1	148.4
60	124.7	151.3	154.8
120	94	147.8	148.1
AUC (mg.min/dL)	13,483.20	17,705.70	16,833.80

Plasma Insulin (ng/mL)

0	2.00	1.23	1.26
30	1.71	1.33	1.64
60	2.86	1.51	1.92
120	2.32	1.24	1.41
AUC (ng.min/mL)	278.84	163.74	196.25*

-18-

<sup>1</sup>Aged (26- month old) Fisher 344 rats were injected with GHRH analog (2 $\mu$ g/kg) for 6 weeks. For comparison, data obtained from young (2 month old) untreated Fisher 344 rats is included. AUC is the area under the plasma glucose- and plasma insulin- vs. time curves. \* Denotes values are significantly different than that observed in aged control animals.

The data of Tables 1 through 3 demonstrate that inducing growth hormone release causes an improvement in glycemic control, increased insulin sensitivity, and increased insulin secretion. Thus, the administration of a growth hormone releasing agent is an effective therapy for NIDDM and other insulin resistance states.

The principles, preferred embodiments and modes of operation of the present invention have been described in the foregoing specification. The invention which is intended to be protected herein, however, is not to be construed as limited to the particular forms disclosed, since they are to be regarded as illustrative rather than restrictive.

Variations and changes may be made by those skilled in the art without departing from the spirit of the invention.

-19-

We claim:

1. The use of growth hormone releasing agent, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful for treating insulin resistance in a mammal.

2. The use as claimed in Claim 1 wherein the growth hormone releasing agent is GHRH, a functional analog of GHRH, an agonist of a GHRH receptor, or a pharmaceutically acceptable salt of the foregoing.


3. The use as claimed in any one of Claims 1 and 2 wherein the growth hormone releasing agent is a compound of the formula:

X1-A2-Asp-Ala-Ile-Phe-Thr-A8-A9-Tyr-Arg-Lys-Val-Leu-A15-Gln-Leu-Ser-Ala-Arg-Lys-A22-Leu-Gln-A25-Ile-A27-Ser-Arg-Y-Z-T (SEQ ID NO:2)

wherein:

A2 = Ile, Val, Thr, or Gly  
A8 = Asn, Ala, Leu, Ser, or Thr;  
A9 = Ser, Ala, Leu, Thr, or Asn;  
A15 = Gly, Ala, Thr, or Leu;  
A22 = Ala or Leu;  
A25 = Asp or Glu;  
A27 = Met, Leu, or Norleucine;  
Y = absent, or an amino acid sequence from 1 to 15 amino acids;  
Z = absent, or an amino acid sequence of from 1 to 32 amino acids;  
T = a carboxyl terminal group represented by the formula  $-COOR_a$ ,  $-CR_aO$ ,  $-CONHNHR_a$ ,  $-CON(R_a)(R_b)$  or  $CH_2OR_a$  wherein  $R_a$  and  $R_b$  independently are lower alkyl, hydrogen;  
X1 is an acyl group represented by the formula

-20-



wherein

$R_1$  = hydrogen, methyl, ethyl, hydroxyethyl, phenyl,  
 or phenyl substituted by halo, lower alkyl,  
 lower alkoxy, hydroxy, nitro, amino,  
 acetamido, trifluoromethyl,  $-CH_2-OH$ , or  
 sulfamido; or a 5 or 6 membered heterocycle  
 containing one or more of N, O, or S;


$a$  = zero, 1, 2, or 3;

$b$  = zero or 1;

$c$  = zero or 1;

$d$  = zero to 12;

$R_2$  = H,  $CH_3$ ,  $CH_2OH$ , p-hydroxybenzyl, or



$e$  = zero to 5;

$A$  = absent, O or S;


$B$  = carbonyl, sulfonyl and sulfinyl;

$R_3$  = methyl, ethyl, hydroxyethyl, amino, hydroxyl,  
 phenyl, or phenyl substituted with halo,  
 alkyl, alkoxy, hydroxy, nitro, amino,  
 acetamido, or sulfamido, or a 5 or 6 member  
 heterocycle containing one or more of N, O, or  
 S;

or a pharmaceutically acceptable salt thereof.

-21-

4. The use as claimed in any one of Claims 1 to 3 wherein X1 is



5 wherein

R<sub>1</sub> = phenyl or phenyl substituted by halo, lower alkyl hydroxy, nitro, or amino;

a = 0, 1 or 2;

b = 1;

10 R<sub>2</sub> = H; and

B = carbonyl.

5. The use as claimed in any one of Claims 1 to 4 wherein X1 is selected from the group consisting of p-chloro hippuroyl, p-methyl hippuroyl, p-nitro hippuroyl, hippuroyl, p-hydroxy hippuroyl, 3-benzoyl propionyl, n-phthaloyl glycyl, N-phenylmalonamidoyl, p-methyl-N-phenylmalonamidoyl, or p-fluorohippuroyl.

20 6. The use as claimed in any one of Claims 1 to 5 wherein Y is the 30-44 amino acid sequence of mature GHRH.

7. The use as claimed in any one of Claims 1 to 6 wherein Z is SEQ ID NO:3 or 4.

25

8. The use as claimed in any one of Claims 1 to 7 wherein X1 is selected from the group consisting of p-methyl hippuroyl or hippuroyl, A2 is Ala, A8 is Asn, A9 is Ser, A15 is Gly, A22 is Leu, A25 is Asp, A27 is Met, Y is the 30-44 amino acid sequence of mature GHRH, Z is the 45-76 amino acid sequence of mature GHRH, and T is -COOR<sub>a</sub>, -CR<sub>a</sub>O, -CONHNHR<sub>a</sub>,

30

-22-

-CON(R<sub>a</sub>)(R<sub>b</sub>) or CH<sub>2</sub>OR<sub>a</sub> wherein R<sub>a</sub> and R<sub>b</sub> independently are lower alkyl, hydrogen.

9. The use as claimed in any one of Claims 1 to 8  
5 wherein X<sub>1</sub> is p-methyl hippuroyl, A<sub>2</sub> is Ala, A<sub>8</sub> is Asn, A<sub>9</sub> is Ser, A<sub>15</sub> is Gly, A<sub>22</sub> is Leu, A<sub>25</sub> is Asp, A<sub>27</sub> is Met, Y is the 30-44 amino acid sequence of mature human GHRH, Z is the 45-76 amino acid sequence of mature human GHRH, and T is -COOH.

10 10. The use as claimed in any one of Claims 1 to 8  
wherein X<sub>1</sub> is hippuroyl, A<sub>2</sub> is Ala, A<sub>8</sub> is Asn, A<sub>9</sub> is Ser, A<sub>15</sub> is Gly, A<sub>22</sub> is Leu, A<sub>25</sub> is Asp, A<sub>27</sub> is Met, Y is the 30-44 amino acid sequence of mature human GHRH, Z is the 45-76 amino acid sequence of mature human GHRH, and T is -COOH.

15 11. A method of treating insulin resistant mammals, which comprises administering to a mammal in need thereof a growth hormone releasing agent or a pharmaceutical acceptable salt thereof.

20 12. A method as claimed in Claim 11 wherein the mammal is a non-insulin dependent diabetic mammal.

25 13. A method as claimed in any one of Claims 11 and 12 wherein the the growth hormone releasing agent is GHRH, a functional analog of GHRH, an agonist of a GHRH receptor, or a pharmaceutically acceptable salt of the foregoing.

30 14. A method as claimed in any one of Claims 11 to 13 wherein the growth hormone releasing agent is a compound of the formula:

35 X<sub>1</sub>-A<sub>2</sub>-Asp-Ala-Ile-Phe-Thr-A<sub>8</sub>-A<sub>9</sub>-Tyr-Arg-Lys-Val-Leu-A<sub>15</sub>-Gln-Leu-Ser-Ala-Arg-Lys-A<sub>22</sub>-Leu-Gln-A<sub>25</sub>-Ile-A<sub>27</sub>-Ser-Arg-Y-Z-T (SEQ ID NO:2)



-23-

wherein:

A2 = Ile, Val, Thr, or Gly

A8 = Asn, Ala, Leu, Ser, or Thr;

A9 = Ser, Ala, Leu, Thr, or Asn;

5 A15 = Gly, Ala, Thr, or Leu;

A22 = Ala or Leu;

A25 = Asp or Glu;


A27 = Met, Leu, or Norleucine;

10 Y = absent, or an amino acid sequence from 1 to 15 amino acids;

Z = absent, or an amino acid sequence of from 1 to 32 amino acids;

15 T = a carboxyl terminal group represented by the formula  $-\text{COOR}_a$ ,  $-\text{CR}_a\text{O}$ ,  $-\text{CONHNHR}_a$ ,  $-\text{CON}(\text{R}_a)(\text{R}_b)$  or  $\text{CH}_2\text{OR}_a$  wherein  $\text{R}_a$  and  $\text{R}_b$  independently are lower alkyl, hydrogen;

X1 is an acyl group represented by the formula



20 wherein

R<sub>1</sub> = hydrogen, methyl, ethyl, hydroxyethyl, phenyl, or phenyl substituted by halo, lower alkyl, lower alkoxy, hydroxy, nitro, amino, acetamido, trifluoromethyl,  $-\text{CH}_2\text{-OH}$ , or sulfamido; or a 5 or 6 membered heterocycle containing one or more of N, O, or S;

a = zero, 1, 2, or 3;


b = zero or 1;

c = zero or 1;

30 d = zero to 12;

R<sub>2</sub> = H, CH<sub>3</sub>, CH<sub>2</sub>OH, p-hydroxybenzyl, or

-24-



e = zero to 5;


A = absent, O or S;

B = carbonyl, sulfonyl and sulfinyl;

5 R<sub>3</sub> = methyl, ethyl, hydroxyethyl, amino, hydroxyl, phenyl, or phenyl substituted with halo, alkyl, alkoxy, hydroxy, nitro, amino, acetamido, or sulfamido, or a 5 or 6 member heterocycle containing one or more of N, O, or S;

10 or a pharmaceutically acceptable salt thereof.

15 15. A method as claimed in any one of Claims 11 to 14 wherein X1 is



wherein

R<sub>1</sub> = phenyl or phenyl substituted by halo, lower alkyl hydroxy, nitro, or amino;

20 a = 0, 1 or 2;

b = 1;

R<sub>2</sub> = H; and

B = carbonyl.

25 16. A method as claimed in any one of Claims 11 to 15 wherein X1 is selected from the group consisting of p-chloro hippuroyl, p-methyl hippuroyl, p-nitro hippuroyl, hippuroyl, p-hydroxy hippuroyl, 3-benzoyl propionyl, n-phthaloyl glyceryl, N-phenylmalonamidoyl, p-methyl-N-phenylmalonamidoyl, or p-fluorohippuroyl.

30

-25-

17. A method as claimed in any one of Claims 11 to 16 wherein Y is the 30-44 amino acid sequence of mature GHRH.

5 18. A method as claimed in any one of Claims 11 to 17 wherein Z is SEQ ID NO:3 or 4.

10 19. A method as claimed in any one of Claims 11 to 18 wherein X1 is selected from the group consisting of p-methyl hippuroyl or hippuroyl, A2 is Ala, A8 is Asn, A9 is Ser, A15 is Gly, A22 is Leu, A25 is Asp, A27 is Met, Y is the 30-44 amino acid sequence of mature GHRH, Z is the 45-76 amino acid sequence of mature GHRH, and T is  $-COOR_a$ ,  $-CR_aO$ ,  $-CONHNHR_a$ ,  $-CON(R_a)(R_b)$  or  $CH_2OR_a$  wherein  $R_a$  and  $R_b$  independently are lower alkyl, hydrogen.

20 20. A method as claimed in any one of Claims 11 to 19 wherein X1 is p-methyl hippuroyl, A2 is Ala, A8 is Asn, A9 is Ser, A15 is Gly, A22 is Leu, A25 is Asp, A27 is Met, Y is the 30-44 amino acid sequence of mature human GHRH, Z is the 45-76 amino acid sequence of mature human GHRH, and T is  $-COOH$ .

25 21. A method as claimed in any one of Claims 11 to 20 wherein X1 is hippuroyl, A2 is Ala, A8 is Asn, A9 is Ser, A15 is Gly, A22 is Leu, A25 is Asp, A27 is Met, Y is the 30-44 amino acid sequence of mature human GHRH, Z is the 45-76 amino acid sequence of mature human GHRH, and T is  $-COOH$ .

30 22. A method of treating an insulin resistant mammal substantially as herein before described.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/14286

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61K 38/27, 38/28, 38/00

US CL :514/3, 12, 21; 530/303, 324

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/3, 12, 21; 530/303, 324

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

NONE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 5,187,151 (CLARK et al.) 16 February 1993, see entire document.	1, 2, 11, 12, 22
X	US, A, 4,988,675 (FROESCH et al.) 29 January 1991, see entire document.	1, 2, 11, 12, 22
X	US, A, 5,126,324 (CLARK et al.) 30 June 1992, see entire document.	1, 2, 11, 12, 22
X	US, A, 5,093,317 (LEWIS et al.) 03 March 1992, see entire document.	1, 2, 11, 12, 22

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

14 NOVEMBER 1996

Date of mailing of the international search report

21 JAN 1997

 Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

P. Lynn Touzeau, Ph.D.

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/14286

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 3-10, 13-21  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

